Your browser is no longer supported. Please, upgrade your browser.
CDTX Cidara Therapeutics, Inc. monthly Stock Chart
Cidara Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.65 Insider Own0.90% Shs Outstand43.21M Perf Week-4.72%
Market Cap109.41M Forward P/E- EPS next Y-1.77 Insider Trans32.58% Shs Float35.34M Perf Month-24.14%
Income-67.30M PEG- EPS next Q-0.29 Inst Own65.20% Short Float5.44% Perf Quarter-33.15%
Sales10.20M P/S10.73 EPS this Y48.80% Inst Trans5.52% Short Ratio7.96 Perf Half Y-32.21%
Book/sh0.68 P/B3.56 EPS next Y-11.30% ROA-92.70% Target Price- Perf Year6.14%
Cash/sh1.01 P/C2.40 EPS next 5Y- ROE-165.60% 52W Range1.30 - 4.45 Perf YTD-36.98%
Dividend- P/FCF- EPS past 5Y-9.90% ROI-87.30% 52W High-47.67% Beta1.75
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low79.12% ATR0.21
Employees68 Current Ratio1.80 Sales Q/Q-87.40% Oper. Margin- RSI (14)41.12 Volatility6.14% 9.30%
OptionableYes Debt/Eq0.27 EPS Q/Q-619.50% Profit Margin- Rel Volume0.87 Prev Close2.42
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume241.63K Price2.33
Recom1.60 SMA20-6.74% SMA50-17.49% SMA200-25.69% Volume127,082 Change-3.78%
Sep-04-19Upgrade Wedbush Neutral → Outperform $2 → $4
Jul-26-18Initiated Citigroup Buy $8
Apr-21-17Initiated Raymond James Strong Buy
Apr-17-17Reiterated H.C. Wainwright Buy $18 → $14
Apr-12-17Initiated Ladenburg Thalmann Buy $11.25
Apr-11-17Resumed Wedbush Outperform $13
Feb-22-17Upgrade WBB Securities Sell → Hold $7.25
Feb-22-17Reiterated H.C. Wainwright Buy $25 → $18
Dec-21-16Resumed Leerink Partners Outperform
Dec-19-16Initiated H.C. Wainwright Buy $25
Sep-23-16Downgrade WBB Securities Hold → Sell $10.50
Oct-09-15Upgrade WBB Securities Sell → Hold $13
May-11-15Initiated Wedbush Outperform $22
May-11-15Initiated Needham Buy $20
May-11-15Initiated Leerink Partners Outperform $24
May-11-15Initiated Jefferies Buy $25
Apr-23-15Initiated WBB Securities Sell $13
Nov-16-20 08:00AM  
Nov-15-20 07:35AM  
Nov-12-20 11:58AM  
Nov-11-20 04:05PM  
Nov-05-20 09:00PM  
Nov-01-20 08:41AM  
Oct-29-20 12:35PM  
Oct-21-20 08:00AM  
Oct-13-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 09:58AM  
Sep-02-20 08:19AM  
Aug-13-20 06:05PM  
Aug-04-20 08:00AM  
Jul-27-20 08:00AM  
Jul-19-20 10:02AM  
Jul-17-20 08:00AM  
Jul-05-20 10:02PM  
Jun-29-20 08:00AM  
Jun-23-20 08:00AM  
Jun-11-20 08:00AM  
Jun-04-20 09:33AM  
May-20-20 08:45AM  
May-13-20 06:05PM  
May-05-20 04:30PM  
Apr-28-20 08:00AM  
Apr-07-20 08:00AM  
Mar-31-20 12:00PM  
Mar-04-20 07:30AM  
Feb-27-20 12:00PM  
Feb-18-20 08:00AM  
Feb-12-20 05:30PM  
Feb-11-20 06:25AM  
Jan-22-20 07:55AM  
Jan-16-20 07:02AM  
Jan-10-20 08:00AM  
Dec-20-19 10:22AM  
Dec-13-19 05:38AM  
Dec-03-19 08:00AM  
Nov-18-19 08:00AM  
Nov-07-19 09:17PM  
Nov-05-19 08:00AM  
Oct-06-19 08:22PM  
Oct-03-19 10:22AM  
Oct-01-19 10:07AM  
Sep-16-19 04:05PM  
Sep-04-19 02:37PM  
Sep-03-19 12:31PM  
Aug-21-19 08:00AM  
Aug-08-19 04:07PM  
Aug-07-19 07:30AM  
Jul-29-19 07:00AM  
Jul-01-19 09:13AM  
Jun-20-19 11:13AM  
Jun-19-19 01:16PM  
Jun-07-19 09:27AM  
Jun-05-19 08:00AM  
May-22-19 09:00AM  
May-09-19 07:54PM  
Apr-16-19 08:00AM  
Apr-15-19 08:00AM  
Apr-12-19 10:08AM  
Apr-03-19 04:04PM  
Mar-26-19 08:00AM  
Mar-07-19 08:00AM  
Mar-04-19 12:19PM  
Feb-28-19 04:24PM  
Feb-05-19 08:00AM  
Jan-17-19 10:00AM  
Dec-21-18 09:54AM  
Dec-03-18 08:00AM  
Nov-27-18 08:38AM  
Nov-14-18 08:30AM  
Nov-12-18 08:00AM  
Nov-08-18 05:38PM  
Oct-24-18 08:00AM  
Oct-15-18 08:00AM  
Oct-04-18 08:00AM  
Sep-27-18 08:00AM  
Sep-25-18 01:16PM  
Sep-24-18 04:05PM  
Sep-12-18 04:02PM  
Sep-04-18 08:00AM  
Aug-08-18 04:54PM  
Jul-30-18 08:00AM  
Jun-15-18 08:00AM  
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stein JeffreyPresident & CEONov 10Buy2.0050,000100,015347,878Nov 12 06:00 AM
Levine James E.Chief Financial OfficerNov 10Buy2.0150,000100,72050,000Nov 12 06:00 AM
Abdollahian NeilChief Business OfficerJan 03Sale3.422,3408,00351,248Jan 06 05:27 PM
Daruwala PaulChief Operating OfficerJan 03Sale3.422,3408,00353,532Jan 06 05:26 PM
Oien JessicaGeneral Counsel & SecretaryJan 02Sale3.868343,2196,965Jan 06 05:28 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.